Au­dentes’ for­mer CEO launch­es new biotech, with $155M for hives and in­flam­ma­tion

For­mer Au­dentes CEO Na­tal­ie Holles is ready to de­but her next project, and it’s one that’s mu­sic to her ears.

Third Har­mon­ic Bio launched Wednes­day morn­ing with a $105 mil­lion Se­ries B and a plan to change the game in chron­ic ur­ticaria, a con­di­tion with sev­er­al caus­es that caus­es se­vere and de­bil­i­tat­ing hives. Holles, who joined last Au­gust, said Third Har­mon­ic has a lead pro­gram al­ready in the clin­ic and ex­pects to launch a Phase Ib study lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER